<DOC>
	<DOCNO>NCT01845818</DOCNO>
	<brief_summary>This observational study document extend daily clinical practice work productivity affect start adalimumab treatment . Changes employment status work productivity patient AS PsA start Adalimumab note . The relationship employment status , work productivity , disease activity clinical evaluation evaluate . Since AS PsA might invalidate disease strong impact daily life patient , evaluation perform effect disease Quality Life work productivity .</brief_summary>
	<brief_title>Study Ankylosing Spondylitis ( AS ) Psoriatic Arthritis ( PsA ) Patients Evaluate Work Productivity Before After Start Adalimumab Therapy Daily Practice Belgium</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patient &gt; = 18 year &lt; = 50 year Patient diagnose Ankylosing Spondylitis Psoriatic Arthritis Patient initiate Adalimumab ( accord Marketing Authorization Belgian reimbursement criterion ) Patient willing sign Informed Consent Any contraindication Adalimumab specify correspond SmPC Patient previously treat biologics Patient participate AbbViesponsored trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>work productivity</keyword>
	<keyword>multicenter study</keyword>
</DOC>